Concord Drugs Ltd

As of June 30, 2026, Concord Drugs Ltd carries a market capitalization of 1.01B, placing it among publicly traded companies globally. Its enterprise value stands at 1.01B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Concord Drugs Ltd has 13.11M shares outstanding.

As of June 30, 2026, Concord Drugs Ltd trades at a trailing price-to-earnings ratio of 45.01.

As of June 30, 2026, Concord Drugs Ltd trades at an EV/EBITDA multiple of 17.29 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.17 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 22.50 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.01B versus a market cap of 1.01B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

Over the twelve months ended June 30, 2026, Concord Drugs Ltd recorded 8.09M in income tax expense. That works out to an effective tax rate of 28.28, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 28.60M, leaving 20.51M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Concord Drugs Ltd's stock has gained approximately 11.33% over the past 52 weeks. The 50-day moving average sits at 75.44, while the 200-day moving average is 77.22.

Over the twelve months ended June 30, 2026, Concord Drugs Ltd generated 860.69M in revenue and converted that into 20.51M in net income, yielding earnings per share of 1.71. EBITDA reached 58.28M, while operating income came in at 44.79M.

Over the twelve months ended June 30, 2026, Concord Drugs Ltd posted a gross margin of 15.02, reflecting its pricing power and cost economics. The operating margin of 5.20 and net profit margin of 2.38 provide insight into operational efficiency.